| Market Cap | 288.40M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -168.62M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 22.00% |
| Sales | 388.4M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 21.00% |
| Dividend | N/A | Price/Book | 0.37 | EPS next 5Y | - | 52W High Chg | -42.00% |
| Recommedations | - | Quick Ratio | 1.14 | Shares Outstanding | 85.07M | 52W Low Chg | 2,191.00% |
| Insider Own | 24.99% | ROA | -2.33% | Shares Float | 58.98M | Beta | 1.24 |
| Inst Own | 17.41% | ROE | -30.98% | Shares Shorted/Prior | -/- | Price | 3.39 |
| Gross Margin | 56.33% | Profit Margin | -44.86% | Avg. Volume | 382 | Target Price | - |
| Oper. Margin | -3.29% | Earnings Date | Aug 22 | Volume | 50 | Change | 0.00% |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women's Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
